methyl 4-(pyrimidin-4-ylamino)benzoate | 881401-58-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-(pyrimidin-4-ylamino)benzoate
• 英文别名: 4-(Pyrimidin-4-ylamino)-benzoic acid methyl ester；4-(Pyrimidin-4-ylamino)benzoic acid methyl ester
• CAS: 881401-58-7
• 化学式: C₁₂H₁₁N₃O₂
• 分子量: 229.238
• InChiKey: WJVFNVKOUAIMKU-UHFFFAOYSA-N

物化性质

• 沸点：
  406.7±25.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 4-(pyrimidin-4-ylamino)benzoate 、 5-氨基-3-苯基-1,2,4-噻重氮 在 三甲基铝 作用下， 以 甲苯 为溶剂， 生成 N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-4-(pyrimidin-4-ylamino)-benzamide
  参考文献：
  名称：

  Pyrimidine benzamide-based thrombopoietin receptor agonists

  摘要：

  A series of pyrimidine benzamide-based thrombopoietin receptor agonists is described. The lead molecule contains a 2-amino-5-unsubstituted thiazole, a group that has been associated with idiosyncratic toxicity. The potential for metabolic oxidation at C-5 of the thiazole, the likely source of toxic metabolites, was removed by substitution at C-5 or by replacing the thiazole with a thiadiazole. Potency in the series was improved by modifying the substituents on the pyrimidine and/or on the thiazole or thiadiazole pendant aryl ring. In vivo examination revealed that compounds from the series are not highly bioavailable. This is attributed to low solubility and poor permeability. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.038
• 作为产物：
  描述：

  4-(6-chloro-pyrimidin-4-yl-amino)-benzoic acid methyl ester 在 钯 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 methyl 4-(pyrimidin-4-ylamino)benzoate
  参考文献：
  名称：

  Thrombopoietin Receptor Agonists

  摘要：

  公式（I）的化合物可用作促进血小板生成和巨核细胞生成的促进剂，其中A、B、D、E、W、X、Y、Z、R1和R2如上所定义。

  公开号：

  US20080076771A1

文献信息

• THIENOPYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS
  申请人：Aicher Babette

  公开号：US20100056548A1

  公开（公告）日：2010-03-04

  The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

  本发明涉及包含噻唑嘧啶化合物的新型药物组合物。此外，本发明涉及使用本发明的噻唑嘧啶化合物制备预防和/或治疗可以受到Mnk1和/或Mnk2（Mnk2a或Mnk2b）及/或其变体的激酶活性抑制影响的疾病的药物组合物。
• TROMBOPOIETIN RECEPTOR AGONISTS
  申请人：Pfizer Products Incorporated

  公开号：EP1794156A2

  公开（公告）日：2007-06-13
• US8633201B2
  申请人：——

  公开号：US8633201B2

  公开（公告）日：2014-01-21
• [EN] TROMBOPOIETIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR DE THROMBOPOIETINE
  申请人：PFIZER PROD INC

  公开号：WO2006033005A2

  公开（公告）日：2006-03-30

  A compound of the formula (I) useful as promoters of thrombopoiesis and megakaryocytopoiesis, wherein A, B, D, E, W, X, Y, Z, R1 and R2 are defined as above.
• Pyrimidine benzamide-based thrombopoietin receptor agonists
  作者：Lawrence A. Reiter、Chakrapani Subramanyam、Emilio J. Mangual、Christopher S. Jones、Marc I. Smeets、William H. Brissette、Sandra P. McCurdy、Paul D. Lira、Robert G. Linde、Qifang Li、Fangning Zhang、Amy S. Antipas、Laura C. Blumberg、Jonathan L. Doty、James P. Driscoll、Michael J. Munchhof、Sharon L. Ripp、Andrei Shavnya、Richard M. Shepard、Diana Sperger、Lisa M. Thomasco、Kristen A. Trevena、Lilli A. Wolf-Gouveia、Liling Zhang

  DOI：10.1016/j.bmcl.2007.07.038

  日期：2007.10

  A series of pyrimidine benzamide-based thrombopoietin receptor agonists is described. The lead molecule contains a 2-amino-5-unsubstituted thiazole, a group that has been associated with idiosyncratic toxicity. The potential for metabolic oxidation at C-5 of the thiazole, the likely source of toxic metabolites, was removed by substitution at C-5 or by replacing the thiazole with a thiadiazole. Potency in the series was improved by modifying the substituents on the pyrimidine and/or on the thiazole or thiadiazole pendant aryl ring. In vivo examination revealed that compounds from the series are not highly bioavailable. This is attributed to low solubility and poor permeability. (C) 2007 Elsevier Ltd. All rights reserved.